Fitness Innovator Dragon Door Releases ‘Get Strong’ Exercise Program by Al Kavadlo & Danny Kavadlo, exclusively for the TriadXP Fitness App

LITTLE CANADA, Minn., Oct. 27, 2020 /PRNewswire/ — Dragon Door Publications, Inc. and Triad Fitness Group, LLC, creator of the TriadXP fitness platform, announced the upcoming release of an in-app version of Al Kavadlo and Danny Kavadlo’s ” Get Strong” exercise program. “Get Strong” is the ultimate 16-week transformation program for gaining muscle and strength—using the power of progressive calisthenics. Al and Danny Kavadlo, two exceptional personal trainers, specialize in bodyweight training as a singular method to build an impressive physique, increase strength, and improve athletic performance, mobility, and flexibility. Plus, the new TriadXP in-app version makes it easier and hassle-free for users to perform their workouts and track their results anywhere, anytime.

“If you want to get as strong as possible, you need intelligent progression,” said John Du Cane, CEO of Dragon Door Publications. “That’s why ‘Get Strong’ is such a phenomenal program, and using the TriadXP fitness app to perform it and track your results makes it even more effective.”

The Kavadlo brothers’ plan starts with building a proper foundation. From there, it gradually progresses you through four phases of strength, giving you the proper progressions and programming details to take you beyond what you ever thought possible. The brothers have also outdone themselves with incredible exercise visuals. Users will find this in-app exercise program packed with well-thought-out, clearly delivered guidance, and beautiful imagery.

The “Get Strong” in-app exercise program will be available in both the Dragon Door and TriadXP online stores. Exercisers can perform it with the free TriadXP fitness app, which provides workout guidance, tracking, and portability; it can be streamed to a mobile device or downloaded to a user’s device for offline performance in remote training areas. TriadXP’s in-app exercise programs provide users with audio and visual workout cues and tracks duration, reps, distance, and resistance while exercising. This premium fitness program from the Kavadlo brothers has been delivering extraordinary results for years but hasn’t been available on mobile devices…until now!

About Dragon Door Publications
Dragon Door Publications is a publisher of innovative fitness content that offers effective, safe, and proven methods for maintaining a high level of health and physical performance over the longterm. The company is best known for having launched the modern kettlebell movement in 2001. Learn more at www.dragondoor.com

About TriadXP.com
TriadXP.com, a fitness content platform from Triad Fitness Group, provides services and technology to allow content providers to convert text-based programs and related exercise imagery and videos into in-app exercise programs to be performed and tracked with the TriadXP mobile app. The app is free and compatible with iOS and Android devices. TriadXP is making workouts better for everyone. Learn more at www.triadxp.com

Contact: John Du Cane
Tel: +1 651-487-3828
Email: [email protected]

View original content to download multimedia: http://www.prnewswire.com/news-releases/fitness-innovator-dragon-door-releases-get-strong-exercise-program-by-al-kavadlo–danny-kavadlo-exclusively-for-the-triadxp-fitness-app-301160644.html

SOURCE Dragon Door Publications

Source Article

Read more

LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect

UPPSALA, SWEDEN – LIDDS AB (publ) announces that intratumoral injection of NZ-TLR9, NanoZolid (NZ) formulation of a Toll-Like Receptor 9 (TLR9), results in strong antitumoral efficacy combined with prominent antitumoral immune responses in mouse tumor models. NZ-TLR9 forms an intratumoral depot which releases the TLR9 agonist for least 6 weeks and thus minimizes the need for repeated injections. Furthermore, we have identified both intratumoral- and plasma biomarkers needed to measure the activity of NZ-TLR9 in clinical trials.

LIDDS has completed a preclinical data package using a TLR9 agonist formulated with NanoZolid®(NZ-TLR9) showing that a single NZ-TLR9 injection is reducing tumor growth and improves the survival of mice, with increase of intratumoral cytotoxic T- cells and activated dendritic cells. The TLR9 agonist is released during at least 6 weeks with equal in vivo efficacy which minimizes the need for repeated injections, which are needed when using standard formulated TLR9 agonists. In addition, the study also identified plasma biomarkers which are suitable to measure the biological activity of NZ-TLR9 in coming clinical trial.

-I’m really happy to see our convincing preclinical data package with NanoZolid formulated TLR9, especially the six weeks of controlled release with strong anti-tumor effect. The results indicate that NanoZolid technology®, with controlled and sustained drug release, can be used to treat deep lying cancer tumors. These tumors are not suitable to be treated with standard TLR9 due to the necessity of weekly injections. The planning for a Phase I study treating solid tumors with intratumoral NZ-TLR9 is ongoing and we plan to start the study towards the second half of 2021, commented Monica Wallter, CEO of LIDDS.

About TLRs and TLR9
Toll-like receptors (TLRs) are key targets in the search for new treatments against cancer. TLRs are expressed on various immune cells, including dendritic cells, and upon activation they initiate the body’s immune response. TLR9 activation leads to an immunologically active tumor environment with recruitment of the cytotoxic T cells which are necessary for an antitumor response in immunotherapy. Thus, TLR9 agonists can convert immunologically “cold” tumors to immunologically “hot” tumors. The most promising target cancers for the TLR9 project are head and neck cancer, prostate cancer, sarcomas and lymphomas. These malignancies are diagnosed in around 2 million patients each year. The market for TLR agonists is expected to be worth hundreds of millions of dollars over the coming years.  

For additional information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, [email protected]

This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above on October 26, 2020 at 08:30 CET.

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid

Read more

Canaccord Predicts Over 100% Rally for These 3 “Strong Buy” Stocks

After passing one speed bump, is the market heading towards more bumps in the road? Following the September sell-off, there has been a surge in COVID-19 cases and limited progress on the next stimulus package. In addition, the likelihood of a Biden victory in the November elections increased.

At the same time, however, the broader market has been ramping up, with the NYSE Cumulative Advance/Decline line reaching a record high and the percentage of SPX components trading above their 10-day moving averages landing at 93% for the first time since early April.

Weighing in for Canaccord, strategist Tony Dwyer commented, “The strength of the broad market driven by the economy recovery beneficiaries has been dramatic, and while we believe the market should remain volatile (in both directions) into year end, our positive fundamental core thesis driven by excess liquidity and a synchronized global recovery suggests inevitable periods of weakness following these type ramps should be used as an opportunity to add equity exposure.”

Turning Dwyer’s outlook into concrete recommendations, Canaccord’s analysts have pinpointed three stocks that could soar in the year ahead, with over 100% upside potential forecasted for each. What’s more, after using TipRanks’ database, we found out that all three have scored enough positive reviews from the broader analyst community to earn a “Strong Buy” consensus rating.

Zynerba Pharmaceuticals (ZYNE)

Developing next-generation transdermally-delivered cannabinoid therapeutics, Zynerba Pharmaceuticals wants to help improve the lives of patients with rare and near-rare neuropsychiatric conditions. With shares changing hands for $3.65, Canaccord believes that the share price presents an attractive entry point.

This summer, ZYNE revealed that in the CONNECT-FX pivotal trial evaluating Zygel, its transdermal cannabidiol gel, in Fragile X syndrome (FXS), the therapy did not achieve statistical significance on its primary or secondary endpoints in the full analysis set, or 210 patients. That being said, it did demonstrate significance on the primary endpoint in patients with full methylation of the FMR1 gene, which was an ad-hoc pre-planned analysis, and secondary endpoints were promising.

Of the patients in the trial, 80% had full methylation, and the company estimates 60% of the 71,000 U.S. FXS patients fall into this category. To this end, ZYNE will meet with the FDA to discuss the next steps for potential approval in this indication, likely in 2H20.

Writing for Canaccord, 5-star analyst Sumant Kulkarni believes that “the key to ZYNE stock lies in the outcome of the company’s interactions with the FDA on its clinical programs for Zygel… It is always difficult to second-guess what the agency might do, but a ‘good’ outcome would involve ZYNE being potentially able to file Zygel for approval in fully-methylated FXS patients. Given there are no products approved for FXS, such an outcome, with perhaps a confirmatory trial to be run, cannot be ruled out.”

Given this result, Kulkarni argues ZYNE will now target the fully-methylated FXS patients. With the analyst seeing the targeting of this subgroup as “the best way forward for its FXS program,”

Read more